What is the recommended dose of fenbendazole for an individual animal, based on its weight? How much fenbendazole will it take to treat a specific number of animals? Which Safe-Guard® and Panacur® formulation is the most appropriate and cost‑effective option in a particular instance?
The answers to these and other questions are just a few clicks away with Merck Animal Health’s new Safe-Guard® mobile application.
This one-of-a-kind tool makes it easy for veterinarians and producers to quickly calculate the volume and amount of fenbendazole required based on the number of animals to be treated, the animal’s weight, and the selected formulation of Safe-Guard®, Panacur® or Panacur® Aquasol™.
The Safe-Guard® mobile application also includes an optional cost comparison feature to help users select the most cost-effective formulation and presentation of fenbendazole to meet their specific needs.
Other features include in-app access to product labels for all formulations of Safe-Guard®, Panacur® and Panacur® Aquasol™, as well as selected studies and a resource section containing helpful information and articles.
“Merck Animal Health has always been committed to providing veterinarians and producers with value-added products and services that promote the well-being of animals and help increase productivity and efficiency,” says Douglas Wong, Product Manager, Farm Animal Business Unit. “Our goal in developing the Safe-Guard® mobile application was to create an easy-to-use, practical calculator and resource tool that helps save time and money by taking the guesswork out of fenbendazole administration.”
The Safe-Guard® mobile application can be used to calculate fenbendazole dosages, quantities and costs for four different species: cattle, swine, horses and poultry.
The Safe-Guard® mobile application for both iOS and Android is now available for download on the Apple Store and Google Play.
About Merck Animal Health Canada
For over a century, Merck has been a global healthcare leader working to help the world be well. Merck Animal Health, known as MSD Animal Health outside Canada and the United States, is the global animal health business unit of Merck. Through its commitment to the Science of Healthier Animals™, Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit http://www.merck-animal-health.ca or connect with us on Twitter @MerckAHCanada.
Forward-Looking Statement of Merck & Co. Inc., Kenilworth, NJ, USA
This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2017 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
Safe-Guard® and Panacur® are registered trademarks of Intervet International B.V. Used under license.
AquasolTM is a trademark of Intervet International B.V. Used under license.
MERCK® is a registered trademark of Merck Canada Inc.
© 2019 Intervet Canada Corp. All rights reserved.